- Previous Close
5.66 - Open
5.60 - Bid 5.56 x 100
- Ask 5.65 x 100
- Day's Range
5.47 - 5.75 - 52 Week Range
3.25 - 10.45 - Volume
478,555 - Avg. Volume
928,960 - Market Cap (intraday)
474.855M - Beta (5Y Monthly) 0.61
- PE Ratio (TTM)
-- - EPS (TTM)
-0.51 - Earnings Date Nov 25, 2024 - Nov 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
35.47
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
www.anavex.comRecent News: AVXL
View MorePerformance Overview: AVXL
Trailing total returns as of 10/3/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AVXL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AVXL
View MoreValuation Measures
Market Cap
479.52M
Enterprise Value
340.76M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.69
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-5.54
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.43%
Return on Equity (ttm)
-30.03%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-41.53M
Diluted EPS (ttm)
-0.51
Balance Sheet and Cash Flow
Total Cash (mrq)
138.76M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-19.06M
Research Analysis: AVXL
View MoreCompany Insights: AVXL
AVXL does not have Company Insights